Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 443

1.

Novel ruthenium complexes ligated with 4-anilinoquinazoline derivatives: synthesis, characterisation and preliminary evaluation of biological activity.

Ji L, Zheng W, Lin Y, Wang X, Lü S, Hao X, Luo Q, Li X, Yang L, Wang F.

Eur J Med Chem. 2014 Apr 22;77:110-20. doi: 10.1016/j.ejmech.2014.02.062. Epub 2014 Mar 1.

PMID:
24631730
2.

Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands.

Zhang Y, Zheng W, Luo Q, Zhao Y, Zhang E, Liu S, Wang F.

Dalton Trans. 2015 Aug 7;44(29):13100-11. doi: 10.1039/c5dt01430a.

PMID:
26106875
3.

Complexation with organometallic ruthenium pharmacophores enhances the ability of 4-anilinoquinazolines inducing apoptosis.

Zheng W, Luo Q, Lin Y, Zhao Y, Wang X, Du Z, Hao X, Yu Y, Lü S, Ji L, Li X, Yang L, Wang F.

Chem Commun (Camb). 2013 Nov 11;49(87):10224-6. doi: 10.1039/c3cc43000f. Erratum in: Chem Commun (Camb). 2013 Dec 28;49(100):11826.

PMID:
23856988
4.

Synthesis, antitumor evaluation and docking study of novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor (EGFR) inhibitors.

Rao GW, Xu GJ, Wang J, Jiang XL, Li HB.

ChemMedChem. 2013 Jun;8(6):928-33. doi: 10.1002/cmdc.201300120. Epub 2013 May 2.

PMID:
23640754
5.

Synthesis, characterization, screening and docking analysis of 4-anilinoquinazoline derivatives as tyrosine kinase inhibitors.

Lü S, Zheng W, Ji L, Luo Q, Hao X, Li X, Wang F.

Eur J Med Chem. 2013 Mar;61:84-94. doi: 10.1016/j.ejmech.2012.07.036. Epub 2012 Jul 27.

PMID:
22867529
6.

Synthesis and reactivity of the aquation product of the antitumor complex trans-[Ru(III)Cl4(indazole)2]-.

Cebrián-Losantos B, Reisner E, Kowol CR, Roller A, Shova S, Arion VB, Keppler BK.

Inorg Chem. 2008 Jul 21;47(14):6513-23. doi: 10.1021/ic800506g. Epub 2008 Jun 14.

PMID:
18553904
7.

Isomeric [RuCl2(dmso)2(indazole)2] complexes: ruthenium(II)-mediated coupling reaction of acetonitrile with 1H-indazole.

Reisner E, Arion VB, Rufińska A, Chiorescu I, Schmid WF, Keppler BK.

Dalton Trans. 2005 Jul 21;(14):2355-64. Epub 2005 Jun 15.

PMID:
15995743
8.

In vitro and in vivo biological activity screening of Ru(III) complexes involving 6-benzylaminopurine derivatives with higher pro-apoptotic activity than NAMI-A.

Trávníček Z, Matiková-Mal'arová M, Novotná R, Vančo J, Stěpánková K, Suchý P.

J Inorg Biochem. 2011 Jul;105(7):937-48. doi: 10.1016/j.jinorgbio.2011.04.002. Epub 2011 Apr 12.

PMID:
21536006
9.

Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents.

Yassen AS, Elshihawy HE, Said MM, Abouzid KA.

Chem Pharm Bull (Tokyo). 2014;62(5):454-66.

10.

Study of ruthenium(II) complexes with anticancer drugs as ligands. Design of metal-based phototherapeutic agents.

Cini R, Tamasi G, Defazio S, Corsini M, Zanello P, Messori L, Marcon G, Piccioli F, Orioli P.

Inorg Chem. 2003 Dec 1;42(24):8038-52.

PMID:
14632524
12.

Solvent assisted formation of ruthenium(III) and ruthenium(II) hydrazone complexes in one-pot with potential in vitro cytotoxicity and enhanced LDH, NO and ROS release.

Jayanthi E, Kalaiselvi S, Padma VV, Bhuvanesh NS, Dharmaraj N.

Dalton Trans. 2016 Jan 28;45(4):1693-707. doi: 10.1039/c5dt03849a.

PMID:
26699435
13.

Synthesis of iridium and ruthenium complexes with (N,N), (N,O) and (O,O) coordinating bidentate ligands as potential anti-cancer agents.

Lucas SJ, Lord RM, Wilson RL, Phillips RM, Sridharan V, McGowan PC.

Dalton Trans. 2012 Dec 7;41(45):13800-2. doi: 10.1039/c2dt32104a. Epub 2012 Sep 27.

PMID:
23015068
14.

Reactions of potent antitumor complex trans-[Ru(III)Cl4(indazole)2]- with a DNA-relevant nucleobase and thioethers: insight into biological action.

Egger A, Arion VB, Reisner E, Cebrián-Losantos B, Shova S, Trettenhahn G, Keppler BK.

Inorg Chem. 2005 Jan 10;44(1):122-32.

PMID:
15627368
15.

Discovery of novel 4-anilinoquinazoline derivatives as potent inhibitors of epidermal growth factor receptor with antitumor activity.

Xu YY, Li SN, Yu GJ, Hu QH, Li HQ.

Bioorg Med Chem. 2013 Oct 1;21(19):6084-91. doi: 10.1016/j.bmc.2013.06.070. Epub 2013 Jul 10.

PMID:
23962660
16.

Discovery and investigation of anticancer ruthenium-arene Schiff-base complexes via water-promoted combinatorial three-component assembly.

Chow MJ, Licona C, Yuan Qiang Wong D, Pastorin G, Gaiddon C, Ang WH.

J Med Chem. 2014 Jul 24;57(14):6043-59. doi: 10.1021/jm500455p. Epub 2014 Jul 15.

PMID:
25023617
17.

Tuning of redox potentials for the design of ruthenium anticancer drugs -- an electrochemical study of [trans-RuCl(4)L(DMSO)](-) and [trans-RuCl(4)L(2)](-) complexes, where L = imidazole, 1,2,4-triazole, indazole.

Reisner E, Arion VB, Guedes da Silva MF, Lichtenecker R, Eichinger A, Keppler BK, Kukushkin VY, Pombeiro AJ.

Inorg Chem. 2004 Nov 1;43(22):7083-93.

PMID:
15500346
18.

Hetero-multinuclear ruthenium(III)/platinum(II) complexes that potentially exhibit both antimetastatic and antineoplastic properties.

Anderson CM, Taylor IR, Tibbetts MF, Philpott J, Hu Y, Tanski JM.

Inorg Chem. 2012 Dec 3;51(23):12917-24. doi: 10.1021/ic301981s. Epub 2012 Nov 14.

PMID:
23150984
19.

Ruthenium(II) carbonyl complexes containing S-methylisothiosemicarbazone based tetradentate ligand: synthesis, characterization and biological applications.

Selvamurugan S, Ramachandran R, Viswanathamurthi P.

Biometals. 2013 Oct;26(5):741-53. doi: 10.1007/s10534-013-9649-8. Epub 2013 Jun 19.

PMID:
23780567
20.

Synthesis, characterization, antiproliferative and anti-metastatic properties of two ruthenium-DMSO complexes containing 2,2'-biimidazole.

Tan C, Hu S, Liu J, Ji L.

Eur J Med Chem. 2011 May;46(5):1555-63. doi: 10.1016/j.ejmech.2011.01.074. Epub 2011 Feb 26.

PMID:
21354673

Supplemental Content

Support Center